colitis

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

ABSTRACT Patients were less tolerant of CBD-rich botanical extract compared with placebo, taking on average one-third fewer capsules, and having more compliance-related protocol deviations (principally insufficient exposure), prompting identification of a per protocol (PP) analysis set. The primary endpoint was negative; end of treatment remission rates were similar for CBD-rich botanical extract (28%) and placebo …

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Read More »

Aug 31 2019

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer

ABSTRACT By focusing the attention on hemp nonpsychoactive cannabinoids, CBD has been demonstrated to be useful in the treatment of different inflammatory ailments, including bowel diseases (e.g., Crohn’s and ulcerative colitis), neuronal diseases (e.g., Parkinson and Alzheimer), and a wide range of inflammatory skin diseases (e.g., atopic dermatitis and psoriasis) [21]. SOURCE

Aug 29 2019

Therapeutic Use of Cannabis in Inflammatory Bowel Disease

ABSTRACT These studies show different levels of elements of the ECS in murine and human IBD models. Further delineation of mechanism of action is needed to determine whether these results are pathologic or reactive effects to inflammation. However, cannabinoids appear to have a clear role in gut pathology and offer a potential target for drug …

Therapeutic Use of Cannabis in Inflammatory Bowel Disease Read More »

Aug 26 2019

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

ABSTRACT Experimental evidence gathered from preclinical IBD models and conducted in rodents point to a strong potential of the ECS components to serve as drug targets in inflammatory diseases of the intestine. Data suggest a homeostatic role of the ECS in the gut. Accordingly, it is believed that the enhancement of endocannabinoid signaling, as observed …

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Read More »

Aug 26 2019

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer

Therapeutic Use of Cannabis in Inflammatory Bowel Disease

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

JOIN OUR NEWSLETTER

CONNECT WITH US

About

LEARN

Shop

These statements have not been evaluated by the FDA. This product is not intended diagnose, treat, cure or prevent disease.